Fig. 6
CPP30-Lipo/CDKACT4 reports the CDK4 inhibitor pharmacodynamics in vivo. a The chemical structures of molecular probes of CPP30-Lipo/CDKA4. b The activation of CPP30-Lipo/CDKA4 within cells. c Fluorescence images of mice bearing MCF-7 tumor injected with CPP30-Lipo/CDKACT4 before and after gavage of sterile water for 7 days, or before and after treatment with 150 mg/kg palbociclib daily for 7 days. The fluorescence signals were measured in radiance counts per cm2 per second per steradian (p/s/cm2/sr) (left). Magnetic resonance imaging (MRI) of mice in (right). (Reproduced from Gao, Y. Y. et al. In vivo visualization of fluorescence reflecting CDK4 activity in a breast cancer mouse model. MedComm (2020) 3, e136 (2022).)
